- Third Harmonic Bio (THRD, Financial) stockholders overwhelmingly approve liquidation plan with 99.9% of voting shares in favor.
- The company anticipates an initial distribution of $5.30-$5.35 per share in Q3 2025, with total distributions estimated between $5.30-$5.44 per share.
- Phase 1 clinical data for THB335 shows 85% serum tryptase reduction, with Phase 2 trial preparations completed.
Third Harmonic Bio, Inc. (THRD) announced that its stockholders have approved the company's Plan of Liquidation and Dissolution with a commanding 99.9% of voting shares in favor during the Annual Meeting held on June 5, 2025. The company plans an initial distribution of $5.30 to $5.35 per share slated for the third quarter of 2025, with overall distributions expected to reach between $5.30 and $5.44 per share. This distribution projection does not account for potential cash inflows from asset sales, including the sale of THB335.
In conjunction with the dissolution plan, Third Harmonic Bio has reported positive results from an additional cohort in its Phase 1 clinical trial of THB335, a KIT inhibitor. The trial showed an 85% reduction in serum tryptase levels at a 100mg daily dose, demonstrating a promising safety profile with mostly mild adverse events. The company has completed all necessary activities for Phase 2 trials targeting chronic spontaneous urticaria and is preparing to submit regulatory filings to the FDA.
As part of its strategic dissolution plan, THRD is initiating a sale process for THB335 and its associated intellectual property. This move aims to maximize shareholder value while effectively leveraging the promising clinical data from THB335, despite the company's decision to wind up operations. Interested parties are encouraged to reach out for more details on the sale process.